跳至主要内容
临床试验/NCT04711382
NCT04711382已完成不适用

The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience

University Hospital, Antwerp1 个研究点 分布在 1 个国家目标入组 438 人开始时间: 2018年1月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
438
试验地点
1
主要终点
Time in Range

研究概览

简要总结

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

详细描述

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T<70 and T<54 mg/dl) and time above range (T>180 and T>250 mg/dl).

Retrospective analysis Two-center study

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
16 Years 至 100 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes patients
  • Duration of diabetes > 2 years
  • Using CGM for > 6 months

排除标准

  • Using SMBG
  • Pregnancy
  • Using glucocorticoids or immunosuppressive agents
  • Active oncological problem

结局指标

主要结局

Time in Range

时间窗: 12 months

Time in target range at 12 months

次要结局

  • Time above range(6 months & 12 months)
  • Time below range(6 months & 12 months)
  • Time in Range(6 months)
  • Change in HbA1c(6 months & 12 months)
  • Coefficient of variation(6 months & 12 months)
  • Change in weight(6 months & 12 months)
  • Change in insulin doses(6 months & 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验